MENU
+Compare
INTS
Stock ticker: NASDAQ
AS OF
Aug 6 closing price
Price
$0.27
Change
-$0.02 (-6.90%)
Capitalization
7.11M

INTS Intensity Therapeutics Forecast, Technical & Fundamental Analysis

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers... Show more

INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for INTS with price predictions
Aug 06, 2025

INTS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for INTS turned positive on August 05, 2025. Looking at past instances where INTS's MACD turned positive, the stock continued to rise in of 18 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INTS's RSI Oscillator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 29 cases where INTS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where INTS advanced for three days, in of 88 cases, the price rose further within the following month. The odds of a continued upward trend are .

INTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 29, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INTS as a result. In of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.277) is normal, around the industry mean (18.047). P/E Ratio (0.000) is within average values for comparable stocks, (58.309). INTS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.504). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (276.800).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

INTS is expected to report earnings to fall 27.27% to -15 cents per share on August 18

Intensity Therapeutics INTS Stock Earnings Reports
Q2'25
Est.
$-0.16
Q1'25
Missed
by $0.04
Q4'24
Missed
by $0.95
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.04
The last earnings report on May 13 showed earnings per share of -21 cents, missing the estimate of -18 cents. With 2.53M shares outstanding, the current market capitalization sits at 7.11M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1 Enterprise Drive
Phone
+1 203 221-7381
Employees
17
Web
https://www.intensitytherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PBT15.150.22
+1.47%
Permian Basin Royalty Trust
LARK25.020.32
+1.30%
Landmark Bancorp
MIR21.540.04
+0.19%
Mirion Technologies
RS285.98-1.80
-0.63%
Reliance
ALZN2.27-0.11
-4.62%
Alzamend Neuro Inc.

INTS and Stocks

Correlation & Price change

A.I.dvisor tells us that INTS and ACAD have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and ACAD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
+10.32%
ACAD - INTS
28%
Poorly correlated
-1.66%
CCCC - INTS
27%
Poorly correlated
-4.29%
OABI - INTS
25%
Poorly correlated
+4.62%
GPCR - INTS
25%
Poorly correlated
-0.60%
CLGN - INTS
24%
Poorly correlated
+0.09%
More